Bank of New York Mellon Corp Sells 622 Shares of Stevanato Group S.p.A. (NYSE:STVN)

Bank of New York Mellon Corp decreased its stake in shares of Stevanato Group S.p.A. (NYSE:STVN) by 3.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,706 shares of the company’s stock after selling 622 shares during the quarter. Bank of New York Mellon Corp’s holdings in Stevanato Group were worth $364,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Van Berkom & Associates Inc. bought a new stake in shares of Stevanato Group in the 4th quarter valued at about $39,000. Captrust Financial Advisors grew its holdings in Stevanato Group by 12.7% in the third quarter. Captrust Financial Advisors now owns 13,100 shares of the company’s stock worth $262,000 after purchasing an additional 1,480 shares during the last quarter. First Bank & Trust increased its position in shares of Stevanato Group by 7.3% during the fourth quarter. First Bank & Trust now owns 15,145 shares of the company’s stock worth $330,000 after purchasing an additional 1,036 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Stevanato Group by 18.2% during the 4th quarter. SG Americas Securities LLC now owns 15,546 shares of the company’s stock valued at $339,000 after purchasing an additional 2,389 shares during the last quarter. Finally, Truist Financial Corp boosted its position in shares of Stevanato Group by 4.2% in the 4th quarter. Truist Financial Corp now owns 26,900 shares of the company’s stock worth $586,000 after purchasing an additional 1,073 shares in the last quarter.

Wall Street Analysts Forecast Growth

STVN has been the topic of several research analyst reports. Morgan Stanley reissued an “equal weight” rating and set a $23.00 target price (down previously from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Bank of America raised their target price on Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. William Blair reiterated an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. UBS Group reduced their price objective on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday, March 7th. Finally, Wolfe Research initiated coverage on Stevanato Group in a research report on Friday, December 13th. They issued an “outperform” rating and a $28.00 target price on the stock. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of €25.70 ($27.93).

Stevanato Group Trading Down 0.3 %

Shares of STVN stock opened at €20.25 ($22.01) on Friday. Stevanato Group S.p.A. has a fifty-two week low of €16.56 ($18.00) and a fifty-two week high of €32.98 ($35.85). The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. The stock’s fifty day moving average is €20.90 and its two-hundred day moving average is €20.59. The firm has a market capitalization of $6.13 billion, a P/E ratio of 43.09, a PEG ratio of 7.18 and a beta of 0.60.

Stevanato Group (NYSE:STVN) last issued its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The company had revenue of €352.68 million during the quarter, compared to analysts’ expectations of €346.26 million. Research analysts expect that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.